Find clinical trials

AMBER is a clinical trial to investigate if venetoclax, a medication which promotes cell death (apoptosis), can promote cell death of long-lived HIV infected cells and lead to a reduction of the latent HIV reservoir. The first part in Denmark used different doses of venetoclax to establish the safest dose to use in people with HIV. The second part of the study is taking place both in Aarhus, Denmark and here in Melbourne, Australia. All participants in part 2 of the study will stay on their ART and receive 3 cycles of the optimal dose of venetoclax determined in the first part of the trial. These cycles are 28 days consisting of 14 days on treatment and 14 days off treatment.  The main outcome of the study is to determine the safety of venetoclax in people with HIV and then blood samples will be collected to understand if veneotclax has an effect on the size of the HIV reservoir and whether the drug is leading to the loss of HIV-infected cells.

The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.

This study (ANZHIT-2) aims to improve the treatment protocols in haploidentical (half match) transplants. We will be using more targeted chemotherapy and total body irradiation in the transplants thus improving on their safety and success. We will also compare the cost-effectiveness and quality of life of haploidentical transplants to matched donor transplants.